<?xml version="1.0" encoding="UTF-8"?>
<p>Several limitations were also acknowledged such as: (1) degradation, for example nanoparticles are degraded in the gut following oral administration, or fail to penetrate the mucus barrier and are thus minimally absorbed [
 <xref rid="B199-pharmaceutics-12-00171" ref-type="bibr">199</xref>], (2) undesired interactions with biological molecules that leads to opsonization, uptake by macrophages and reduced plasma half-life [
 <xref rid="B200-pharmaceutics-12-00171" ref-type="bibr">200</xref>], (3) non-specifically absorption that may induce apoptosis and disrupt cell membrane and adverse immunological responses [
 <xref rid="B201-pharmaceutics-12-00171" ref-type="bibr">201</xref>], (4) large dimension for renal clearance therefore cannot be degraded within the body, and are accumulated, leading to toxicity [
 <xref rid="B202-pharmaceutics-12-00171" ref-type="bibr">202</xref>], and (5) scaling up issues and high costs.
</p>
